Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018
SAN DIEGO, November 5, 2018 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing rapid efficacy of MET409, a potent, systemic and sustained non-bile acid farnesoid X receptor (FXR) agonist in a biopsy confirmed nonalcoholic steatohepatitis (NASH)… Read More
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
SAN DIEGO, September 6, 2018 – Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the appointment of Hubert C. Chen, M.D., as Chief Medical Officer, and Andrew Guggenhime as a director of the company. Dr. Chen most recently served as Chief Medical and Scientific Officer… Read More
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced dosing of the first subjects in a Phase 1 randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) trial of its lead product candidate MET409. The trial is a single and… Read More
Metacrine Completes $65 Million Series C Financing
Proceeds will support clinical development of FXR program in NASH and GI diseases San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has completed a Series C financing which raised $65 million in new funds. The investment was led by… Read More
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 3:30 p.m. EDT (12:30 p.m. PDT) in New York City.… Read More
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today presented data showing equivalent efficacy of M480, a potent oral non-bile acid farnesoid X receptor (FXR) agonist for the potential treatment of inflammatory bowel disease (IBD), to anti-IL-12/23, a biologic agent. The oral… Read More
Metacrine Broadens Management Team with Two Key Hires
San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced two new key management appointments. Trisha M. Millican has joined the company as Chief Financial Officer, while Karl F. Cremer, Pharm.D., has been appointed Vice President, Clinical Operations. “I am delighted to… Read More
Metacrine to Present Two Abstracts on its Novel FXR Non-Bile Acid Agonist Program at the EASL International Liver Congress 2017
San Diego, CA – Metacrine, Inc., a leading and innovative biotechnology company focused on drug development for metabolic diseases, announced it will present two abstracts on its novel FXR agonist program at the upcoming International Liver Congress Meeting of the European Association for the Study of Liver Disease (EASL) in Amsterdam, Netherlands. Metacrine has developed… Read More
Metacrine to Present at 30th Annual ROTH Conference
Corporate and panel presentations as part of NASH program San Diego, CA – Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced that Ken Song, MD, President and CEO, will give a corporate presentation and participate in a NASH panel discussion at the 30th Annual ROTH Conference taking place at the Ritz-Carlton… Read More
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
San Diego, CA – Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced it has closed a $22M Series B financing led by new investor New Enterprise Associates (NEA), along with participation from existing investors ARCH, Polaris, venBio, and Alexandria Venture Investments. As part of the new financing, Carol Gallagher, Pharm D,… Read More
Metacrine’s FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.
San Diego, CA – Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Washington, D.C. Metacrine has developed an industry leading… Read More
Metacrine Announces Appointment of Dr. Ken Song as President and Chief Executive Officer
San Diego, CA – Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced the appointment of Ken Song, M.D., as its new president, chief executive officer and director. Dr. Song was most recently co-founder and chief executive officer of Ariosa Diagnostics, which was acquired… Read More
Metacrine Raises $36 Million in Series A Financing
Appoints Neil McDonnell, CEO, Along with Executive Team and Board San Diego, CA – Metacrine, Inc., a biotechnology company focused on targeting metabolic disease through advances in endocrine research, today announced it has raised $36 million in a Series A financing. The financing included participation from Arch Venture Partners, EcoR1 Capital, Polaris Partners and venBio.… Read More